A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed sarcoma of soft tissue

- Patients must have metastatic and/or locally advanced or locally recurrent disease

- Patients must have measurable disease within 4 weeks prior to registration by RECIST
1.1, defined as at least one lesion that can be accurately measured in at least one
dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques
or as >= 10 mm with spiral computed tomography (CT) scan; tumor lesions that are
situated in a previously irradiated area may be considered measurable for the
purposes of this study only if there is evidence of growth of the area following a
course of irradiation that cannot be attributed to necrosis or bleeding into the
tumor

- Patients must have had a minimum of 1 and a maximum of 4 prior chemotherapy regimens
for recurrent/metastatic disease (it will be up to the treating investigator to
define what constitutes a "regimen" in each case); the last dose of systemic therapy
(include tyrosine kinase inhibitors) must have been given at least 4 weeks prior to
initiation of therapy; patients receiving BCNU or mitomycin C must have received
their last dose of such therapy at least 6 weeks prior to initiation of therapy

- Patients with brain metastasis that have been treated with definitive surgery or
radiation and have been clinically stable for 3 months following the procedure with
no neurological signs or symptoms and no requirement for systemic glucocorticoids are
eligible for study

- Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1

- Absolute neutrophil count >= 1.5 x 10^9/l

- Platelets >= 75 x 10^9/l

- Total bilirubin =< 1.5 x upper limit of normal (ULN) (except for patients with known
Gilbert Syndrome)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 x institutional ULN

- Serum creatinine =< 1.5 x ULN

- If urine protein:creatinine (UPC) >= 1, then a 24-hour urine protein must be
assessed; patients must have a 24-hour urine protein value < 1g to be eligible

- Patients must not have current evidence of another malignancy; there are no
restrictions regarding prior history of malignancy

- If female and of childbearing potential, documentation of negative pregnancy test is
required within 7 days prior to first dose; sexually active males and females of
childbearing potential must agree to use adequate contraceptive measures, while on
study and for 30 days after the last dose of study drug; all subjects (and their
partners) must agree to use a highly effective method of contraception; effective
birth control includes (a) intrauterine device (IUD) plus one barrier method; or (b)
2 barrier methods; effective barrier methods are male or female condoms, diaphragms,
and spermicides (creams or gels that contain a chemical to kill sperm)

- Note: oral, implantable, or injectable contraceptives may be affected by
cytochrome P450 interactions, and are not considered effective for this study

- Adverse events related to prior tumor-specific therapy must have resolved to less
than or equal to National Cancer Institute (NCI) Common Terminology Criteria of
Adverse Events (CTCAE) (version 4) grade 1 prior to study entry (except alopecia)

- Patients taking cytochrome P450 (CYP)3A4 inducers at the time of
screening/registration are still eligible for participation, but whenever possible
these medications should be discontinued or changed to one that is not an inducer

- NOTE: No washout period is required

- NOTE: It will be up to the treating investigator's discretion to assess whether
or not the risk of discontinuing or changing the medication is higher or lower
than the risk of continuing it while on study for the individual patient

- Patients must have the ability to understand and the willingness to sign a written
informed consent document; signed and dated informed consent must be obtained prior
to registration on trial

Exclusion Criteria:

- Patients with any one of the following sarcoma histological subtypes will not be
eligible for participation: alveolar soft-part sarcoma, chondrosarcoma,
dermatofibrosarcoma, Ewing sarcoma, gastrointestinal stromal tumor (GIST), Kaposi
sarcoma, mixed mesodermal tumor/carcinosarcoma, osteosarcoma, and low grade (grade 1)
sarcomas; NOTE: Myxoid liposarcoma with t(12;16) or t(22;22) is permitted;
rhabdomyosarcoma (Embryonal, Alveolar, pleomorphic), interdigitating dendritic
sarcoma, giant cell tumor of bone

- Patients who have had major surgery within 21 days or those who have not recovered
from adverse events associated with surgery to =< grade 1 will not be eligible for
participation; excluded from such considerations are surgical changes not expected to
improve, e.g. removal of muscle tissue; patients may be on replacement
glucocorticoids for pre-existing glucocorticoid deficiency (e.g. Addison's disease)

- Patients receiving any other investigational agents will not be eligible for
participation

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to tivozanib will not be eligible for participation

- Patients with serious and/or unstable pre-existing medical, psychiatric, or other
conditions that could interfere with safety, provision of informed consent, or
compliance to study procedures and requirements will not be eligible for
participation, including but not limited to:

- Uncontrolled intercurrent illness

- Ongoing or active infection including HIV, active hepatitis B or C)

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness/social situations that would limit compliance with study
requirements will not be eligible for participation

- Pregnant women and women who are breast-feeding will not be eligible for
participation

- Patients with a history or clinical evidence of central nervous system (CNS)
metastases or leptomeningeal carcinomatosis will not be eligible for participation;
NOTE: Individuals who have previously-treated CNS metastases, are asymptomatic, and
have had no requirement for steroids or anti-seizure medications for 3 months prior
to first dose of study drug are the exception; screening with CNS imaging studies
such as CT or magnetic resonance imaging (MRI) is required only if clinically
indicated or if the subject has a history of CNS metastases

- Patients with clinically significant gastrointestinal (GI) abnormalities that may
increase the risk for GI bleeding will not be eligible for participation; these
include, but are not limited to:

- Active peptic ulcer disease

- Known intraluminal metastatic lesion/s with risk of bleeding

- Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
GI conditions with increased risk of perforation

- History of abdominal fistula, GI perforation, or intra-abdominal abscess within
28 days prior to beginning study treatment

- Clinically significant (> 1/2 teaspoon) hemoptysis or gastrointestinal
hemorrhage in the past 6 months

- Patients with evidence of active bleeding or bleeding diathesis will not be eligible
for participation; recent hemoptysis would be >= 1/2 teaspoon of red blood within 8
weeks before first dose of study drug

- Patients with clinically significant GI abnormalities that may affect absorption of
investigational product will not be eligible for participation; these include but are
not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel

- Patients with a corrected QT interval (QTc) > 480 msecs using Bazett's formula (QT
Interval / square root(RR interval)) will not be eligible for participation

- Patients with left ventricular ejection fraction (LVEF) < 50% will not be eligible
for participation

- NOTE: patients who do not meet the cutoff for LVEF may be re-screened at a later
date and, if eligible then, may be enrolled in the study

- Patients with a history of any one or more of the following cardiovascular conditions
within the past 6 months will not be eligible for participation:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease\

- Class III or IV congestive heart failure, as defined by the New York Heart
Association (NYHA)

- Patients with poorly controlled hypertension [defined as systolic blood pressure
(SBP) of >= 140 mmHg or diastolic blood pressure (DBP) of >= 90mmHg] will not be
eligible for participation

- Note: Initiation or adjustment of antihypertensive medication(s) is permitted
prior to study entry; following antihypertensive medication initiation or
adjustment, blood pressure (BP) must be re-assessed three times at approximately
2-minute intervals; at least 24 hours must have elapsed between
anti-hypertensive medication initiation or adjustment and BP measurement; these
three values will be averaged to obtain the mean diastolic blood pressure and
the mean systolic blood pressure; the mean SBP / DBP ratio must be < 140/90 mmHg
in order for a subject to be eligible for the study

- Patients with cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
will not be eligible for participation

- Note: subjects with recent DVT who have been therapeutically coagulated for at
least 6 weeks are eligible

- Patients who had major surgery or trauma within 28 days prior to first dose of
investigational product and/or presence of any non-healing wound, fracture, or ulcer
(procedures such as catheter placement not considered to be major surgery) will not
be eligible for participation

- Patients with known endobronchial lesions and/or lesions infiltrating major pulmonary
vessels will not be eligible for participation

- Note: tumor abutting the vessel is acceptable, but contiguous tumor and vessel
is not; CT with contrast is strongly recommended to evaluate such lesions